"The voice for cancer physicians and their patients in Massachusetts."
Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma. Read More.
Massachusetts Society of Clinical Oncologists ©2023
860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: email@example.com